OSCR

Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice.

Overview

Authors: Ke Ren1, Ziyang Yuan2, Lei Lei2, Ziyuan Xiao2, Ningyi Ma2, Guodong Wang1, Ningyi Sun1, Tai Yang3, Zhiyong Chang4, Liang Qin4, Ying Xu5, Dahai Yu4, Lizhou Jia6, Haishi Qiao2
  1. Department of Clinical Microbiology, School of Laboratory Medicine, Chengdu Medical College, Chengdu, China
  2. Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, China
  3. School of Pharmacy, Chengdu Medical College, Chengdu, China
  4. Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
  5. The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
  6. Central Laboratory, Bayannur Hospital, Bayannur, China
Journal: Nature communications, volume 17, issue 1, article 5465
Dates: received 22 November 2024; accepted 2 April 2026; published online 20 April 2026
Type: Research article · Language: English
License: CC BY-NC-ND
Identifiers: DOI 10.1038/s41467-026-72067-7 · PMID 42009673 · PMCID PMC13284352 · OpenAlex W7155000913
Open access: gold, a free copy (OpenAlex)
Status: data only
Categories: human (organism), mouse (organism), other condition (population)
Methods: Spectral & time-frequency, Statistics, Evoked potentials, Connectivity, fMRI & imaging
Keywords: Biotechnology, Tumour immunology, Radiotherapy
MeSH: BCG Vaccine*, Brain Neoplasms*, Glioblastoma*, Mycobacterium bovis*, Tumor-Associated Macrophages*, Animals, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Female, Humans, Macrophages, Mice, Mice, Inbred C57BL, Phagocytosis, Reactive Oxygen Species, Trained Immunity (* major topic)
Topic: Immune responses and vaccinations (Immunology, Immunology and Microbiology), according to OpenAlex
Funding: China Postdoctoral Science Foundation (2021M693953)
Citations: cited by 1 paper (Europe PMC); 50 references in the paper

Abstract

The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data availability statement

The paper has a data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

Read it in the paper: doi.org/10.1038/s41467-026-72067-7.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 29 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 14 authors, 3 keywords, 16 MeSH terms, 1 funder, 48 references.

Cite

This paper

Ren, K., Yuan, Z., Lei, L., Xiao, Z., Ma, N., Wang, G., Sun, N., Yang, T., Chang, Z., Qin, L., Xu, Y., Yu, D., Jia, L., & Qiao, H. (2026). Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice. Nature communications, 17(1), 5465. https://doi.org/10.1038/s41467-026-72067-7

BibTeX

@article{ren2026engineered,
author = {Ren, Ke and Yuan, Ziyang and Lei, Lei and Xiao, Ziyuan and Ma, Ningyi and Wang, Guodong and Sun, Ningyi and Yang, Tai and Chang, Zhiyong and Qin, Liang and Xu, Ying and Yu, Dahai and Jia, Lizhou and Qiao, Haishi},
title = {{Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice}},
journal = {Nature communications},
year = {2026},
month = apr,
volume = {17},
number = {1},
pages = {5465},
publisher = {Nature Publishing Group},
issn = {2041-1723},
doi = {10.1038/s41467-026-72067-7},
url = {https://doi.org/10.1038/s41467-026-72067-7},
pmid = {42009673},
pmcid = {PMC13284352}
}

RIS

TY - JOUR
AU - Ren, Ke
AU - Yuan, Ziyang
AU - Lei, Lei
AU - Xiao, Ziyuan
AU - Ma, Ningyi
AU - Wang, Guodong
AU - Sun, Ningyi
AU - Yang, Tai
AU - Chang, Zhiyong
AU - Qin, Liang
AU - Xu, Ying
AU - Yu, Dahai
AU - Jia, Lizhou
AU - Qiao, Haishi
TI - Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice
T2 - Nature communications
J2 - Nat Commun
PY - 2026
DA - 2026/04/20
VL - 17
IS - 1
SP - 5465
SN - 2041-1723
PB - Nature Publishing Group
DO - 10.1038/s41467-026-72067-7
UR - https://doi.org/10.1038/s41467-026-72067-7
LA - en
ER -

CSL-JSON

{
"id": "10.1038/s41467-026-72067-7",
"type": "article-journal",
"title": "Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice",
"container-title": "Nature communications",
"author": [
{
"family": "Ren",
"given": "Ke"
},
{
"family": "Yuan",
"given": "Ziyang"
},
{
"family": "Lei",
"given": "Lei"
},
{
"family": "Xiao",
"given": "Ziyuan"
},
{
"family": "Ma",
"given": "Ningyi"
},
{
"family": "Wang",
"given": "Guodong"
},
{
"family": "Sun",
"given": "Ningyi"
},
{
"family": "Yang",
"given": "Tai"
},
{
"family": "Chang",
"given": "Zhiyong"
},
{
"family": "Qin",
"given": "Liang"
},
{
"family": "Xu",
"given": "Ying"
},
{
"family": "Yu",
"given": "Dahai"
},
{
"family": "Jia",
"given": "Lizhou"
},
{
"family": "Qiao",
"given": "Haishi"
}
],
"container-title-short": "Nat Commun",
"volume": "17",
"issue": "1",
"page": "5465",
"DOI": "10.1038/s41467-026-72067-7",
"PMID": "42009673",
"PMCID": "PMC13284352",
"ISSN": "2041-1723",
"publisher": "Nature Publishing Group",
"URL": "https://doi.org/10.1038/s41467-026-72067-7",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
20
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1126/sciadv.adz1686
Persistent microglial activation following neonatal CMV infection mediates neurodegeneration.
Journal: Science advances
In common: other condition, mouse, 2 references
[2] doi:10.1038/s41467-026-74888-y
Engineered zwitterion-nanodelivery for precision targeting of brain metastases.
Journal: Nature communications
In common: other condition, mouse, 1 reference
[3] doi:10.1038/s41467-026-72746-5
Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response.
Journal: Nature communications
In common: other condition, mouse, 1 reference
[4] doi:10.1080/2162402x.2026.2656053
PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.
Journal: Oncoimmunology
In common: other condition, mouse, 1 reference
[5] doi:10.1038/s41586-026-10451-5
Androgen loss accelerates brain tumour growth via HPA axis activation.
Journal: Nature
In common: other condition, mouse, 1 reference
[6] doi:10.1158/1078-0432.ccr-25-3525 [code]
Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
In common: other condition, 1 reference
[7] doi:10.1186/s13293-026-00927-4 [code]
Gene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma treatment resistance in females.
Journal: Biology of sex differences
In common: other condition, 1 reference
[8] doi:10.1016/j.crmeth.2026.101480 [code]
DeepFaceMouse enables scalable prediction of large-scale brain activity from facial dynamics in mice.
Journal: Cell reports methods
In common: mouse, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.